NRB Inc. (KOSDAQ:475230)
South Korea flag South Korea · Delayed Price · Currency is KRW
16,280
+990 (6.47%)
Aug 8, 2025, 3:30 PM KST

Checkpoint Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
1.831.572.55-5.02
Debt / EBITDA Ratio
3.332.633.0318.66
Asset Turnover
-0.400.50-
Inventory Turnover
-9.075.03-
Quick Ratio
0.110.070.370.35
Current Ratio
0.210.190.550.75
Return on Equity (ROE)
-6.10%24.65%-
Return on Assets (ROA)
-2.95%7.40%-
Return on Capital (ROIC)
-4.00%10.31%-
Return on Capital Employed (ROCE)
5.90%10.00%15.30%4.80%
Buyback Yield / Dilution
--43.49%-702.71%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.